Abstract
Background: A change in the HER2 gene copy number can be detected at 16–20% cent of gastric cancer patients. ToGA trial proved that chemotherapy combined with targeted HER-2 antibodies improved survival of this group by 20%, which prompted a registration of Trastuzumab as the first-line treatment of this patient group; its administration is indicated until the onset of progression.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
